N
Nereid Therapeutics
A pioneer of the biomolecular condensate field and one of the world’s leading experts in intracellular liquid-liquid phase separation
About Nereid Therapeutics
Nereid Therapeutics is a biotechnology startup that operates in the field of intracellular liquid-liquid phase separation (LLPS), a process similar to the movement of a lava lamp. This process occurs within living cells and plays a crucial role in gene regulation and various disease processes. Nereid's work is based on the pioneering research of its academic founder, Clifford Brangwynne, Ph.D., a leading expert in the field of biomolecular condensate.
Nereid's business model revolves around the development and application of technologies that can measure and influence LLPS in mammalian cells. The company uses advanced microscopy and computer vision to observe the formation and behavior of membrane-less droplets within cells, which are key to the LLPS process. By understanding and manipulating these droplets, Nereid aims to discover small molecules that can alter protein interactions associated with diseases.
The company's primary market is the healthcare sector, specifically in the development of treatments for intractable diseases such as cancers, neurodegenerative illnesses, and inflammatory disorders. Nereid's approach combines soft matter physics and cell biology, using machine learning to enhance insights and accelerate the translation of these insights into medicinal chemistry.
In terms of revenue generation, Nereid likely operates on a business-to-business model, partnering with larger pharmaceutical companies to develop and commercialize its discoveries. The company's unique approach to disease treatment could potentially offer a new avenue for the development of therapeutics, making it an attractive partner for larger entities in the pharmaceutical industry.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Nov 2020 | $50M | $200M | Clifford P. Brangwynne · Apple Tree Partners | — |
| SPINOUTOther financing | Jan 2020 | $0 | — | Princeton University | — |
Growth signals
Latest recorded traffic for Nereid Therapeutics is 2K monthly website visits, down 16.7% over the last three months. Nereid Therapeutics's team declined 60% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Nereid Therapeutics in the Boston ecosystem
The Nereid Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Apple Tree Partners- CBClifford P. Brangwynne
Other known investors1 additional known investor
Princeton University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Nereid Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Nereid Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









